Novartis’ monoclonal antibody ianalumab achieved statistically significant results in two separate phase 3 studies targeting Sjögren’s syndrome and primary immune thrombocytopenia (ITP). This dual-mechanism B-cell depleting antibody demonstrated reductions in disease activity and maintenance of platelet levels compared to placebo, marking a breakthrough for Sjögren’s, which lacks approved treatments. Novartis plans regulatory submissions based on these pivotal data. The successes underscore a resurgence in Novartis’ immunology pipeline following earlier setbacks with other autoimmune candidates.